Diagnosing chronic pulmonary aspergillosis (CPA) is complicated, and limited data regarding the detection of galactomannan (GM) in clinical specimens are available. The purpose of this study was to evaluate the detection of GM in bronchoalveolar lavage fluid (BALF) and serum and to assess its utility for diagnosing CPA. We retrospectively reviewed the diagnostic and clinical characteristics of 144 patients with and without CPA whose BAL and serum were examined for the presence of GM in Nagasaki University Hospital, Japan. The Platelia Aspergillus enzyme immunoassay (PA EIA) was performed according to the manufacturer's instructions. Of the 144 patients, 18 had CPA and 126 patients did not have CPA. The mean values of BALF GM antigen were 4.535 (range, 0.062-14.120) and 0.430 (range, 0.062-9.285) in CPA and non-CPA patients, respectively. The mean values of serum GM antigen were 1.557 (range, 0.232-5.397) and 0.864 (range, 0.028-8.956) in CPA and non-CPA patients, respectively. PA EIA with BALF is superior to PA EIA with serum, according to receiver operating characteristics analysis; the optimal cut-off values for BALF and serum were 0.4 and 0.7, respectively. The sensitivity and specificity of PA EIA with BALF at a cut-off of 0.4 were 77.2% and 77.0%, respectively. The sensitivity and specificity of PA EIA with serum at a cut-off of 0.7 were 66.7% and 63.5%, respectively. GM testing using BALF showed reasonable sensitivity and specificity as compared to that using serum. Thus, assessing GM levels in BALF may enhance the accuracy of diagnosing CPA.
INTRODUCTION
Chronic forms of pulmonary aspergillosis (CPA) are known as a slowly progressing inflammatory pulmonary syndrome caused by Aspergillus [1, 2] . These chronic forms include semi-invasive aspergillosis [3] , chronic necrotizing pulmonary aspergillosis (CNPA) [4] , chronic cavitary pulmonary aspergillosis (CCPA), chronic fibrosing pulmonary aspergillosis (CFPA), and simple and complex aspergilloma [5] . Hope et al.
indicated [2] that apparently distinct entities do not exist for these subtypes, and they are usually overlapped. The common characteristics of these forms are as follows: (1) underlying pulmonary disorders (e.g., tuberculosis sequelae, bronchiectasis, chronic obstructive pulmonary disease, cystic lesions, and pulmonary fibrosis); (2) low-grade immunosuppression (e.g., low-dose steroid administration, diabetes, collagen diseases, renal disorders, or alcohol consumption) that is related to reduced host immunity; and
(3) less severe findings than those of angioinvasion in histopathology [1, 5, 6] .
Diagnosing CPA is problematic, which causes difficulty in establishing clear definitions of the previously stated subtypes of CPA. There are no reliable diagnostic methods for CPA, and the presence of underlying pulmonary diseases may make the problem worse, because these underlying diseases allow other microorganisms to cause co-infection with Aspergillus. Only Aspergillus antibody testing with the Aspergillus immunodiffusion system is useful, as reported by several previous studies [2, 5, 7, 8] .
Aspergillus galactomannan (GM) is a polysaccharide component of the fungal cell wall that is released during tissue invasion by Aspergillus hyphae. A commercially available Platelia Aspergillus enzyme-linked immunosorbent assay (PA EIA; Bio-Rad Laboratories, Redmond, WA) detects the GM of most Aspergillus species. The overall sensitivity of PA EIA with serum is approximately 61-71%, with a specificity of 89-93% for invasive aspergillosis [9] . However, a fairly low positive rate was obtained among CPA patients in limited studies [7, 8, 10] ; therefore, this method is currently not considered useful for CPA diagnosis.
Bronchoscopy with bronchoalveolar lavage (BAL) is an important tool for diagnosing pulmonary infections including fungal infection. The use of testing BAL fluid (BALF) for diagnosing invasive pulmonary aspergillosis (IPA) of various backgrounds has been reported previously [11] [12] [13] [14] [15] [16] [17] [18] . Moreover, BALF testing compensates for the moderate sensitivity and relatively low positive predictive value (PPV) of serum GM testing.
To date, very few studies have been performed on PA EIA with BALF in CPA patients.
The objective of this study was to assess the use of the PA EIA with BALF for the diagnosis of CPA. CFPA, and simple aspergilloma, were used in this study [2] . Proposed enrollment criteria for prospective clinical studies of CPA by Denning were also used for this study with minor modifications [5] . Patients with CPA had to fulfill the following conditions: This study was approved by the ethical committee of Nagasaki University Hospital, and informed consent was obtained from each patient before bronchoscopic examination.
MATERIALS AND METHODS

Study design, BAL procedure, and GM measurement
Statistical analysis
The sensitivity, specificity, PPV, and negative predictive value (NPV) were calculated for PA EIA with serum and BALF. The Mann-Whitney U test was used to compare paired data (means of GM testing with serum and BALF between CPA and non-CPA groups). False-positive fractions were compared using univariate analysis, and the chi-square test was used for qualitative variables. Correlation coefficients between variables were calculated. Multivariate logistic regression analysis was performed using the variables that were selected from univariate analysis (P < 0.1) and correlation analysis (|r| > 0.224). The optimal threshold level for PA EIA with serum and BALF was determined by receiver operating characteristics (ROC) analysis. This analysis was performed by SPSS ver. 16, software. A P-value < 0.05 was considered statistically significant.
RESULTS
Profile of recruited patients
We studied 18 CPA patients and 126 non-CPA patients (total, 144 patients). Table 1 shows the mean age, sex, and underlying diseases and conditions of the evaluated patients. The mean age of all patients was relatively high at 64.8 years, and 61.8% of these patients were men. Patients with bronchiectasis were the most dominant population, followed by patients with interstitial pneumonia, chronic obstructive pulmonary disease (COPD), and lung cancer. The mean age of the 18 CPA patients was 68.6 years, and 88.9% of these patients were men. COPD, bronchiectasis, and tuberculosis sequelae were predominant as underlying diseases in CPA patients. Other underlying diseases and conditions in non-CPA patients are also listed in Table 1 .
Characteristics of CPA patients
The characteristics of CPA patients are indicated in 
Comparison of GM antigen titers between patients with and without CPA
The mean values of GM antigen in BALF The ROC curve in the generalized estimation equation model for PA EIA is presented in Figure 1 . The area under the curve (AUC) was larger for PA EIA with BALF (0.775) than for PA EIA with serum (0.711). The optimal cut-offs of PA EIA calculated from the ROC curve were 0.4 and 0.7 for BALF and serum, respectively. Table 3 shows the sensitivity, specificity, PPV, and NPV of PA EIA with BALF and serum for diagnosing CPA with a cut-off established by ROC analysis (0.4 for BALF and 0.7 for serum). Both the sensitivity and specificity of PA EIA were superior for BALF than for serum, which was also confirmed by the larger AUC in the ROC analysis.
Factors associated with the false positivity of GM tests in non-CPA patients
Of the 126 non-CPA patients studied, 29 (23.0%) had a positive GM titer in BALF with a cut-off of 0.4. Age, sex, and various conditions such as underlying diseases, drug usage, radiological findings, and fungal isolates from BALF were evaluated to detect the factors associated with false positivity of PA EIA with BALF. Table 4 PA EIA has been approved for the diagnosis of aspergillosis, especially IPA, with a high sensitivity and specificity at a cut-off of 0.5 by using serum. Our previous clinical study showed a low positive rate (48.9% at a cut-off of 0.5) of detecting CPA by using serum.
Similarly, a study in Japan reported that PA EIA positivity was only 50.0% at a cut-off of 0.5 [8] . Thus, PA EIA is not suitable for diagnosing CPA by using serum as a sample [7] . Although the use of BALF instead of serum for the diagnosis of IPA of various backgrounds has been reported previously [11] [12] [13] [14] [15] [16] [17] [18] , the potential use of this test in CPA patients is very limited. The primary objective in this study was to compare the utility of PA EIA with BALF and PA EIA with serum.
The features of CPA patients in this study were as follows: (1) various underlying conditions such as previous tuberculosis infection, COPD, and bronchiectasis; (2) middle-aged to elderly patients; (3) primarily male patients; and (4) a relatively high positive rate for the Aspergillus antibody test (61.1%). These features matched the findings reported in previous studies, including our recent clinical study [7, 19, 20] .
Although beta-lactams with beta-lactamase inhibitors influence the result of PA EIA with serum [21, 22] , no such drugs were used in this study. Furthermore, antifungal drugs were not administered to any patient until at least 4 weeks prior to timing of PA EIA with BALF and serum. Thus, influence of the prior treatment of antibiotics and antifungals on the results of PA EIA can be ignored in this study.
A comparison of actual GM antigen titers between patients with and without CPA indicated that GM titer in the BALF and serum of CPA patients was statistically higher than that in the BALF and serum of non-CPA patients. Our attempt to estimate optimal cut-off values for PA EIA with BALF and serum from ROC curves indicated that the optimal cut-off values for BALF and serum were 0.4 and 0.7, respectively. The sensitivity and specificity of PA EIA by using the new cut-offs showed that BALF is superior to serum as the target sample for diagnosing CPA. However, no dramatic increase was observed in its utility for diagnosing CPA as compared to that reported in a similar study by Park et al. [23] . Park et al. reported that the sensitivity of PA EIA with BALF for a cut-off of 0.5 in 36 patients with single pulmonary cavity containing a fungus ball was 92% [23] . Hence, our result in 18 CPA patients showed a lower sensitivity of 72.2% at a cut-off of 0.4 (61.1% at a cut-off of 0.5). The major difference in the present study and the study by Park et al. was the patient population (subtypes of CPA). In our study, almost all patients had multiple cavities with or without fungus balls; moreover, the complexity of lesions in the lungs due to underlying diseases may have influenced the results of our study. Moreover, because our study was retrospective, the ability to estimate the power of the diagnostic tool was limited.
Because it is also important to assess the false-positive rate for diagnosing CPA by using the PA EIA with BALF, we examined the factors associated with false positivity in non-CPA patients. Our data indicated that presence of bulla on a chest radiograph and detection of Penicillium spp. in BALF were significantly associated with false-positive results of PA EIA with BALF. Both univariate and multivariate analyses confirmed the significance of these factors. Bulla lesions can be colonized by Aspergillus, and PA EIA can detect GM from colonized Aspergillus. Moreover, because PA EIA showed cross-reactivity with some Penicillium spp. in an in vitro study [24] , it is possible to detect Penicillium spp. antigens in BALF by using this method. To the best of our knowledge, this is the first study to identify a relationship between the presence of Penicillium spp. in BALF and false positivity of PA EIA with BALF. There were only four cases of which Aspergillus spp. (A. niger, A. versicolor, and A. flavus) were isolated from BALF by culturing BALF from 126 non-CPA patients; of these, 2 patients were indicated positive by using PA EIA (data not shown). Because Aspergillus is a ubiquitous fungus and may exist in any environment, it is possible that it colonizes the respiratory tract or contaminates the samples during handling. Therefore, careful assessment of the results of PA EIA with BALF is still required. Because some studies, including our previous clinical study (88.6% positivity), have reported the use of the serum Aspergillus precipitins test for detecting antibodies to Aspergillus for CPA patients [1, 7, 8, 19] , a combined use of an antibody test and PA EIA with BALF but not serum may prove potentially useful.
In conclusion, this is the first report to address the use of PA EIA with BALF for the diagnosis of CPA. This test has reasonable sensitivity and specificity at a cut-off of 0.4 as compared to the use of serum. Diagnosis of CPA requires synthetic assessment of clinical, radiological, mycological, and serological factors, and it is apparent that no single serological test is universally applicable. However, PA EIA with BALF may have a potential use for the diagnosis of CPA. Prospective and large-scaled studies are still warranted, and newer biomarkers that reflect a more precise state of CPA are also expected. 
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